Progressive Intermediate-Grade Non-Hodgkin's Lymphoma after High-Dose Therapy and Autologous Peripheral Stem-Cell Transplantation: Changing the Natural History with Monoclonal Antibody Therapy

Clinical Lymphoma

Volumn 1, Issue 1, 2000, Pages 62-66

  Tsai, Donald E ^a,d   Schuster, Stephen J ^a   Matthies, Alexander ^a   Moore, Halle C F ^b   Alavi, Abass ^a   Juweid, Malik E ^c   Goldenberg, David M ^c   Stadtmauer, Edward A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD20; CD22; Epratuzumab; Monoclonal antibody; Non Hodgkin's lymphoma; Relapse; Rituximab; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY;

ARTICLE; AUTOTRANSPLANTATION; B LYMPHOCYTE; BLOOD CELL COUNT; CASE REPORT; DISEASE COURSE; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NECK; NONHODGKIN LYMPHOMA; RADIOGRAPHY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BLOOD CELL COUNT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, INTERMEDIATE-GRADE; MALE; MIDDLE AGED; NECK; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034209308     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.006     Document Type: Article

References (11)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
2. Vose JM, Bierman PJ, Anderson JR, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80:2142-2148.
3. de Lima M, van Besien KW, Giralt SA, et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19:121-127.
4. Vandenberghe E, Pearce R, Taghipour G, et al. Role of a second transplant in the management of poor-prognosis lymphomas: a report from the European blood and bone marrow registry. J Clin Oncol 1997; 15:1595-1600.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
6. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refrac-tory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
7. Tsai D, Moore H, Hardy C, et al. Rituximab (anti-CD20 monoclonal antibody) for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24:521-526.
8. Jmveid M, Matthies A, Alavi A, et al. Conventional and hematopoietic stem-cell-supported radioimmunotherapy (RAIT) with humanized 90Y-112 anti-CD22 monoclonal antibody (Mab) in NHL patients who failed high-dose chemotherapy (HDC). Blood 1999; 94:174a.
9. Juweid ME, Stadtmauer E, Hajjar G, et al. Pharmacokinetics, dosimetry, and initial therpeutic results with 1311-and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res 1999; 5:3292s-3303s.
10. Bhatnagar A, Kroll S, Langmuir V, et al. Clinical experience with iodine-131 anti-Bl antibody for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 1999; 26:970a.
11. Witzig TE, White CA, Gordon LI, et al. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: report of interim results. Blood 1999; 94:631a.